Scott Sukenick's practice focuses on the life sciences. He litigates a wide variety of patent and contract disputes across the pharmaceutical, nutraceutical, biotechnology, and medical device fields. He recently represented Gilead Sciences, Inc. in a bet-the-company arbitration over exclusive rights to Gilead's breakthrough hepatitis C drug, Sovaldi®. In a dispute that turned on the interpretation of a key technical term in a collaboration agreement, the arbitration panel ruled that the competitor had no rights to Sovaldi®. He also recently represented Neptune Technologies & Bioressources, Inc., a pioneer in the research and development of omega-3-rich krill oil products, achieving favorable settlement of patent litigation in the US International Trade Commission and obtaining a temporary restraining order against a potential competitor, preventing exhibition of its products at a major industry trade show.
Download full bio